Identification
- Generic Name
- Farnesol
- DrugBank Accession Number
- DB02509
- Background
A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Farnesol (DB02509)
- Weight
- Average: 222.3663
Monoisotopic: 222.198365454 - Chemical Formula
- C15H26O
- Synonyms
- Not Available
- External IDs
- FEMA NO. 2478, (2Z,6Z)-
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UBile acid receptor agonistHumans UAmine oxidase [flavin-containing] B Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Above foot Protect Neymar Jr Unissex Aerosol, spray 3 mg/100g Topical Baston Industria de Aerossóis Ltda 2023-03-09 Not applicable US 
Deo Pedico Above Neymar Jr Men Aerosol, spray 3 mg/100g Topical Baston Industria de Aerossóis Ltda 2022-11-12 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sesquiterpenoids. These are terpenes with three consecutive isoprene units.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Sesquiterpenoids
- Direct Parent
- Sesquiterpenoids
- Alternative Parents
- Fatty alcohols / Primary alcohols / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic acyclic compound / Farsesane sesquiterpenoid / Fatty acyl / Fatty alcohol / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Primary alcohol / Sesquiterpenoid
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- farnesol (CHEBI:42680) / Acyclic farnesane sesquiterpenoids (LMPR0103010008)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- J03523NK03
- CAS number
- 4602-84-0
- InChI Key
- CRDAMVZIKSXKFV-FBXUGWQNSA-N
- InChI
- InChI=1S/C15H26O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16H,5-6,8,10,12H2,1-4H3/b14-9-,15-11-
- IUPAC Name
- (2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol
- SMILES
- CC(C)=CCC\C(C)=C/CC\C(C)=C/CO
References
- Synthesis Reference
James Millis, "Production of farnesol and geranylgeraniol." U.S. Patent US20030092144, issued May 15, 2003.
US20030092144- General References
- Not Available
- External Links
- PDB Entries
- 1dgp / 6dew / 8ki5
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Aerosol, spray Topical 3 mg/100g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) < 25 °C PhysProp boiling point (°C) 111 °C at 3.50E-01 mm Hg PhysProp - Predicted Properties
Property Value Source Water Solubility 0.0587 mg/mL ALOGPS logP 4.84 ALOGPS logP 4.16 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 16.33 Chemaxon pKa (Strongest Basic) -2.2 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 20.23 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 74.98 m3·mol-1 Chemaxon Polarizability 28.64 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9846 Blood Brain Barrier + 0.9375 Caco-2 permeable + 0.6445 P-glycoprotein substrate Non-substrate 0.5851 P-glycoprotein inhibitor I Non-inhibitor 0.8865 P-glycoprotein inhibitor II Non-inhibitor 0.5696 Renal organic cation transporter Non-inhibitor 0.8179 CYP450 2C9 substrate Non-substrate 0.791 CYP450 2D6 substrate Non-substrate 0.8278 CYP450 3A4 substrate Non-substrate 0.527 CYP450 1A2 substrate Non-inhibitor 0.9046 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.923 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.9088 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.765 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.5055 Biodegradation Ready biodegradable 0.8931 Rat acute toxicity 1.6146 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7838 hERG inhibition (predictor II) Non-inhibitor 0.8377
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 168.3729613 predictedDarkChem Lite v0.1.0 [M-H]- 160.97981 predictedDeepCCS 1.0 (2019) [M+H]+ 168.8028613 predictedDarkChem Lite v0.1.0 [M+H]+ 163.33781 predictedDeepCCS 1.0 (2019) [M+Na]+ 168.0093613 predictedDarkChem Lite v0.1.0 [M+Na]+ 169.43098 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Ligand-activated transcription factor. Receptor for bile acids such as chenodeoxycholic acid, lithocholic acid and deoxycholic acid. Represses the transcription of the cholesterol 7-alpha-hydroxyla...
- Gene Name
- NR1H4
- Uniprot ID
- Q96RI1
- Uniprot Name
- Bile acid receptor
- Molecular Weight
- 55913.915 Da
References
- Downie MM, Sanders DA, Maier LM, Stock DM, Kealey T: Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro. Br J Dermatol. 2004 Oct;151(4):766-75. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Primary amine oxidase activity
- Specific Function
- Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
- Gene Name
- MAOB
- Uniprot ID
- P27338
- Uniprot Name
- Amine oxidase [flavin-containing] B
- Molecular Weight
- 58762.475 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Primary amine oxidase activity
- Specific Function
- Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
- Gene Name
- MAOB
- Uniprot ID
- P27338
- Uniprot Name
- Amine oxidase [flavin-containing] B
- Molecular Weight
- 58762.475 Da
References
- Khalil AA, Davies B, Castagnoli N Jr: Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorg Med Chem. 2006 May 15;14(10):3392-8. doi: 10.1016/j.bmc.2005.12.057. Epub 2006 Feb 3. [Article]
- Sari Y, Khalil A: Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson's Disease. CNS Neurol Disord Drug Targets. 2015;14(6):777-85. [Article]
Drug created at June 13, 2005 13:24 / Updated at July 02, 2020 13:17